Abstract
Some patients suffering from schizophrenia fail to respond to or tolerate adequate doses of available antipsychotic medications. Thus, innovative pharmacotherapeutic approaches, such as augmentation strategies, play an important role in the management of these treatment-resistant patients. A recent case report suggested that the administration of famotidine to a patient suffering from schizophrenia with peptic ulcer disease was associated with improvement in the deficit symptoms of schizophrenia. Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier. Impressed by this finding, famotidine was prescribed to some of our treatment-resistant patients suffering from schizophrenia who demonstrated significant deficit symptoms of schizophrenia. The subjects were 12 (eight male, four female) treatment-resistant psychotic patients whose antipsychotic medications were augmented with famotidine in an open trial. They ranged in age from 21 to 48 years with a mean age of 32.75 years. Seven of the 12 subjects made significant improvement resulting in discharge from hospital. Paranoid disturbances as well as absence of comorbid substance use were predictors of good response to famotidine augmentation of the antipsychotic medications. The results implied that H2 receptor activity in the brain might play a role in the pathogenesis of deficit syndromes in schizophrenia. Further studies of this strategy are recommended, since it may open a window of understanding of the negative (deficit) syndrome and its treatment.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andreasen N. C. The diagnosis of schizophrenia. Schizophr Bull. 1987;13(1):9–22. doi: 10.1093/schbul/13.1.9. [DOI] [PubMed] [Google Scholar]
- Davis J. M., Schaffer C. B., Killian G. A., Kinard C., Chan C. Important issues in the drug treatment of schizophrenia. Schizophr Bull. 1980;6(1):70–87. doi: 10.1093/schbul/6.1.70. [DOI] [PubMed] [Google Scholar]
- Dingemans P. M., Bleeker J. A., Frohn-De Winter M. L. A cross-cultural study of the reliability and factorial dimensions of the Nurses' Observation Scale for Inpatient Evaluation (NOSIE). J Clin Psychol. 1984 Jan;40(1):169–172. [PubMed] [Google Scholar]
- Hafkenscheid A. Psychometric evaluation of the Nurses Observation Scale for Inpatient Evaluation in The Netherlands. Acta Psychiatr Scand. 1991 Jan;83(1):46–52. doi: 10.1111/j.1600-0447.1991.tb05510.x. [DOI] [PubMed] [Google Scholar]
- Honigfeld G., Gillis R. D., Klett C. J. NOSIE-30: a treatment-sensitive ward behavior scale. Psychol Rep. 1966 Aug;19(1):180–182. doi: 10.2466/pr0.1966.19.1.180. [DOI] [PubMed] [Google Scholar]
- Kagevi I., Thorhallsson E., Wählby L. CSF concentrations of famotidine. Br J Clin Pharmacol. 1987 Dec;24(6):849–850. doi: 10.1111/j.1365-2125.1987.tb03261.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kaminsky R., Moriarty T. M., Bodine J., Wolf D. E., Davidson M. Effect of famotidine on deficit symptoms of schizophrenia. Lancet. 1990 Jun 2;335(8701):1351–1352. doi: 10.1016/0140-6736(90)91237-5. [DOI] [PubMed] [Google Scholar]
- Meltzer H. Y., Bastani B., Kwon K. Y., Ramirez L. F., Burnett S., Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl) 1989;99 (Suppl):S68–S72. doi: 10.1007/BF00442563. [DOI] [PubMed] [Google Scholar]
- Philip A. E. Cross-cultural study of the factorial dimensions of the NOSIE. J Clin Psychol. 1977 Apr;33(2):467–468. doi: 10.1002/1097-4679(197704)33:2<467::aid-jclp2270330228>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
- Pickar D., Owen R. R., Litman R. E., Konicki E., Gutierrez R., Rapaport M. H. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry. 1992 May;49(5):345–353. doi: 10.1001/archpsyc.1992.01820050009001. [DOI] [PubMed] [Google Scholar]
- Prell G. D., Green J. P. Histamine as a neuroregulator. Annu Rev Neurosci. 1986;9:209–254. doi: 10.1146/annurev.ne.09.030186.001233. [DOI] [PubMed] [Google Scholar]
- White J. M., Rumbold G. R. Behavioural effects of histamine and its antagonists: a review. Psychopharmacology (Berl) 1988;95(1):1–14. doi: 10.1007/BF00212757. [DOI] [PubMed] [Google Scholar]